All In Biotech

Drug Trial Radar · NCT00141323

Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)

PEARL: Postmenopausal Evaluation And Risk-Reduction With Lasofoxifene

Last checked: Nov 19, 2026Latest source record: Aug 15, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 8,556 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,556

Planned (sponsor's estimate)

Start

Nov 2001

Primary completion

Dec 2007

Study completion Dec 2007

Sponsor

Lead sponsor
Ligand PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 1, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 60 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine the safety and effectiveness of 2 doses of the investigational drug, lasofoxifene, compared to placebo (an inactive substance) in reducing new spinal fractures in women with osteoporosis.

Conditions

  • Osteoporosis

Interventions

  • lasofoxifeneDrug

    0.5 mg once per day, orally

  • placeboOther

    placebo

  • lasofoxifeneDrug

    0.25 mg once per day, orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. New morphometric vertebral fracturesTime frame: 3 years
  2. New cases of breast cancerTime frame: 5 years
  3. New non-vertebral fracturesTime frame: 5 years

Locations

201 sites in 32 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    La Jolla, California

  • Pfizer Investigational Site

    La Jolla, California

  • Pfizer Investigational Site

    La Jolla, California

  • Pfizer Investigational Site

    Palm Desert, California

  • Pfizer Investigational Site

    Palm Springs, California

  • Pfizer Investigational Site

    Palm Springs, California

  • Pfizer Investigational Site

    Poway, California

  • Pfizer Investigational Site

    Rancho Mirage, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Brandon, Florida

  • Pfizer Investigational Site

    Leesburg, Florida

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    West Palm Beach, Florida

  • Pfizer Investigational Site

    Des Plaines, Illinois

  • Pfizer Investigational Site

    Morton Grove, Illinois

  • Pfizer Investigational Site

    Des Moines, Iowa

  • Pfizer Investigational Site

    Bethesda, Maryland

  • Pfizer Investigational Site

    Montgomery Village, Maryland

  • Pfizer Investigational Site

    Arden Hills, Minnesota

  • Pfizer Investigational Site

    Minneapolis, Minnesota

  • Pfizer Investigational Site

    Omaha, Nebraska

  • Pfizer Investigational Site

    Albuquerque, New Mexico

  • Pfizer Investigational Site

    Albuquerque, New Mexico

  • Pfizer Investigational Site

    Centerville, Ohio

  • Pfizer Investigational Site

    Dayton, Ohio

  • Pfizer Investigational Site

    Portland, Oregon

  • Pfizer Investigational Site

    Charleroia, Pennsylvania

  • Pfizer Investigational Site

    Monessen, Pennsylvania

  • Pfizer Investigational Site

    Cordova, Tennessee

  • Pfizer Investigational Site

    Memphis, Tennessee

  • Pfizer Investigational Site

    Dallas, Texas

  • Pfizer Investigational Site

    San Antonio, Texas

  • Pfizer Investigational Site

    Richmond, Virginia

  • Pfizer Investigational Site

    Richmond, Virginia

  • Pfizer Investigational Site

    Richmond, Virginia

Showing 40 of 201 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.